Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

Jan B. Vermorken, Éva Remenár, Carla van Herpen, Thierry Gorlia, Ricard Mesı́a, M. Degardin, John S. Stewart, S. Jelić, Jan Betka, Joachim H. Preiss, Daniëlle Van den Weyngaert, Ahmad Awada, Didier Cupissol, H. Kienzer, A Rey, Isabelle Desaunois, Jacques Bernier, Jean-Louis Lefèbvre

New England Journal of Medicine, 2007

Universitair Ziekenhuis Brussel, Antwerp University Hospital, National Institute of Oncology, Radboud University Medical Center, Radboud University Nijmegen, European Organisation for Research and Treatment of Cancer, Institut Català d'Oncologia, Centre Oscar Lambret, Charing Cross Hospital, Oncology Institute of Vojvodina, University Hospital in Motol, cts CaritasKlinikum Saarbrücken, Ziekenhuisnetwerk Antwerpen Stuivenberg, Institut Jules Bordet, Gefluc Languedoc Roussillon, Kaiser-Franz-Josef-Spital, Sanofi (France), Clinique de Genolier

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1703

Citations

View on Google Scholar

Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back